GLP1R/APLNR Antibody Fusion Protein (Wuxi Accufusionbio Tech )

GLP1R/APLNR抗体融合蛋白(华盛康肽生物)

Report date: 2026/04/09 20:00:21

Base Information

Drug NameGLP1R/APLNR Antibody Fusion Protein (Wuxi Accufusionbio Tech )
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionApelin receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsApelin receptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes MellitusHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuxi Accufusionbio Tech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuxi Accufusionbio Tech Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes MellitusHeart Failure
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A